You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for STF 31
STF 31 is an inhibitor of GLUT1; inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells. Activity causes necrotic cell death in von Hippel-Lindau (VHL)-deficient RCC cells. Also NAMPT inhibitor. Eliminates human pluripotent stem cells from culture with limited toxicity towards differentiated cells.
Compound Libraries for STF 31
Technical Data for STF 31
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for STF 31
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for STF 31
The following data is based on the product molecular weight 423.53. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.36 mL||11.81 mL||23.61 mL|
|5 mM||0.47 mL||2.36 mL||4.72 mL|
|10 mM||0.24 mL||1.18 mL||2.36 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
References for STF 31
References are publications that support the biological activity of the product.
Chan et al (2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci.Transl.Med. 3 94ra70 PMID: 21813754
Adams et al (2014) NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem.Biol. 9 2247 PMID: 25058389
Kropp et al (2015) Inhibition of an NAD+ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells. Stem Cells Transl.Med. 4 483 PMID: 25834119
If you know of a relevant reference for STF 31, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: STF 31, STF 31 supplier, STF31, glut1, glucose, transporters, inhibitors, inhibits, uptake, slc2a1, Glucose, Transporters, NAMPT, ESCs, and, iPSC, 4484, Tocris Bioscience
5 Citations for STF 31
Citations are publications that use Tocris products. Selected citations for STF 31 include:
Xintaropoulou et al (2018) Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer 18 636 PMID: 29866066
Fons et al (2019) PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nat Commun 10 3790 PMID: 31439867
Xintaropoulou et al (2015) A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. Oncotarget 6 25677 PMID: 26259240
Thwe et al (2017) Cell-Intrinsic Glycogen Metabolism Supports Early Glycolytic Reprogramming Required for Dendritic Cell Immune Responses. Cell Metab 26 558 PMID: 28877459
Kropp et al (2015) Inhibition of an NAD+ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells. Mol Cell Biol 4 483 PMID: 25834119
Do you know of a great paper that uses STF 31 from Tocris? Please let us know.
Reviews for STF 31
Average Rating: 5 (Based on 1 Review.)
Have you used STF 31?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.